Form 4 Filing for Adaptive Biotechnologies Corp

Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, reported a sale of 11,000 shares of Common Stock on June 4, 2026, at a price of $18.00 per share. This transaction was executed as part of a Rule 10b5-1 trading plan adopted on December 16, 2025. Following this transaction, Ms. Bobulsky directly owns 416,775 shares of Common Stock. The filing, designated as Form 4, indicates a disposition of shares by an insider.